Literature DB >> 1564478

Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease.

K A Jobst1, A D Smith, C S Barker, A Wear, E M King, A Smith, P A Anslow, A J Molyneux, B J Shepstone, N Soper.   

Abstract

A combination of medial temporal lobe atrophy, shown by computed tomography, and reduced blood flow in the parietotemporal cortex, shown by single photon emission tomography, was found in 86% (44/51) of patients with a clinical diagnosis of senile dementia of the Alzheimer type (SDAT). The same combination of changes was found in four out of 10 patients with other clinical types of dementia and in two out of 18 with no evidence of cognitive deficit. Of the 12 patients who died, 10 fulfilled histopathological criteria for Alzheimer's disease, nine of them having a clinical diagnosis of SDAT, and one a clinical diagnosis of multi-infarct dementia. All 10 patients with histopathologically diagnosed Alzheimer's disease had shown a combination of hippocampal atrophy and reduced parietotemporal blood flow in life. In 10 patients (nine with SDAT) out of 12 in whom the hippocampal atrophy was more noticeable on one side of the brain than on the other the parietotemporal perfusion deficit was also asymmetrical, being greater on the side showing more hippocampal atrophy. These results suggest that the combination of atrophy of the hippocampal formation and reduced blood flow in the parietotemporal region is a feature of dementia of the Alzheimer type and that the functional change in the parietotemporal region might be related to the loss of the projection neurons in the parahippocampal gyrus that innervate this region of the neocortex.

Entities:  

Mesh:

Year:  1992        PMID: 1564478      PMCID: PMC1014723          DOI: 10.1136/jnnp.55.3.190

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  31 in total

1.  Cerebral perfusion as a diagnostic marker of early Alzheimer's disease.

Authors:  I Prohovnik; R Mayeux; H A Sackeim; G Smith; Y Stern; P O Alderson
Journal:  Neurology       Date:  1988-06       Impact factor: 9.910

2.  Early marker for Alzheimer's disease: the atrophic hippocampus.

Authors:  M J de Leon; A E George; L A Stylopoulos; G Smith; D C Miller
Journal:  Lancet       Date:  1989-09-16       Impact factor: 79.321

3.  18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans.

Authors:  E G McGeer; R P Peppard; P L McGeer; H Tuokko; D Crockett; R Parks; H Akiyama; D B Calne; B L Beattie; R Harrop
Journal:  Can J Neurol Sci       Date:  1990-02       Impact factor: 2.104

4.  Alzheimer disease: quantitative analysis of I-123-iodoamphetamine SPECT brain imaging.

Authors:  R S Hellman; R S Tikofsky; B D Collier; R G Hoffmann; D W Palmer; S L Glatt; P G Antuono; A T Isitman; R A Papke
Journal:  Radiology       Date:  1989-07       Impact factor: 11.105

5.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

6.  Demonstration of neurofibrillary tangles in paraffin sections: a quick and simple method using a modification of Palmgren's method.

Authors:  R B Cross
Journal:  Med Lab Sci       Date:  1982-01

7.  Temporal lobe atrophy in patients with Alzheimer disease: a CT study.

Authors:  D K Kido; E D Caine; M LeMay; S Ekholm; H Booth; R Panzer
Journal:  AJNR Am J Neuroradiol       Date:  1989 May-Jun       Impact factor: 3.825

Review 8.  Critical analysis of the use of computer-assisted transverse axial tomography to study human brain in aging and dementia of the Alzheimer type.

Authors:  C DeCarli; J A Kaye; B Horwitz; S I Rapoport
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

9.  Pain in sciatica depresses lower limb nociceptive reflexes to sural nerve stimulation.

Authors:  J C Willer; A Barranquero; M F Kahn; D Sallière
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-01       Impact factor: 10.154

Review 10.  [18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET) in aging and dementia. A decade of studies.

Authors:  J M Hoffman; B H Guze; L R Baxter; J C Mazziotta; M E Phelps
Journal:  Eur Neurol       Date:  1989       Impact factor: 1.710

View more
  37 in total

Review 1.  FDG-PET Contributions to the Pathophysiology of Memory Impairment.

Authors:  Shailendra Segobin; Renaud La Joie; Ludivine Ritz; Hélène Beaunieux; Béatrice Desgranges; Gaël Chételat; Anne Lise Pitel; Francis Eustache
Journal:  Neuropsychol Rev       Date:  2015-08-30       Impact factor: 7.444

2.  Association between medial temporal lobe atrophy on CT and parietotemporal uptake decrease on SPECT in Alzheimer's disease.

Authors:  I Lavenu; F Pasquier; F Lebert; B Jacob; H Petit
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

3.  Brain SPET perfusion in early Alzheimer's disease: where to look?

Authors:  Ingeborg Goethals; Christophe Van De Wiele; Daniel Slosman; Rudi Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08       Impact factor: 9.236

4.  Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Authors:  C Wischik; R Staff
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

5.  Disruption of limbic white matter pathways in mild cognitive impairment and Alzheimer's disease: a DTI/FDG-PET study.

Authors:  Andrea C Bozoki; Igor O Korolev; Nathan C Davis; Lori A Hoisington; Kevin L Berger
Journal:  Hum Brain Mapp       Date:  2011-06-14       Impact factor: 5.038

6.  Initial mini-mental state and cerebral perfusion in Alzheimer's disease.

Authors:  T Ones; I Midi; F Dede; N Tuncer; T Y Erdil; O Onultan; S Ceylan; S Inanir; H T Turoglu
Journal:  Clin Neuroradiol       Date:  2012-01-03       Impact factor: 3.649

7.  Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer's disease.

Authors:  Nicolas Villain; Marine Fouquet; Jean-Claude Baron; Florence Mézenge; Brigitte Landeau; Vincent de La Sayette; Fausto Viader; Francis Eustache; Béatrice Desgranges; Gaël Chételat
Journal:  Brain       Date:  2010-08-05       Impact factor: 13.501

Review 8.  Staging neurodegenerative disorders: structural, regional, biomarker, and functional progressions.

Authors:  Trevor Archer; Richard M Kostrzewa; Richard J Beninger; Tomas Palomo
Journal:  Neurotox Res       Date:  2011-02       Impact factor: 3.911

9.  Cobalamin deficiency, hyperhomocysteinemia, and dementia.

Authors:  Steven F Werder
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-06       Impact factor: 2.570

10.  Cerebral blood flow is an earlier indicator of perfusion abnormalities than cerebral blood volume in Alzheimer's disease.

Authors:  María Lacalle-Aurioles; José M Mateos-Pérez; Juan A Guzmán-De-Villoria; Javier Olazarán; Isabel Cruz-Orduña; Yasser Alemán-Gómez; María-Elena Martino; Manuel Desco
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-15       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.